AMR Benchmark homepage
Now online: 2021 AMR Benchmark
The AMR Benchmark: tracking pharma’s response to drug resistance
The 2021 Antimicrobial Resistance Benchmark compares how pharmaceutical companies are tackling this crisis. This independent report covers R&D, responsible manufacturing, access and stewardship.
Progress on limiting release of antibiotic waste into environment, but gaps remain
More companies set and enforce limits at their own sites, and are now starting to expand these standards to supplier sites.
Pharma companies make limited use of ways to improve access to antibiotics
Just one third of products are covered by any access strategy in any of the low and middle-income countries in scope.
News related to the Antimicrobial Resistance Benchmark
"This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified.”
Dame Sally Davies
Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance and Master of Trinity College, Cambridge